These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30948314)

  • 1. Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
    Lamano JB; Quaggin-Smith JA; Horbinski CM; Tate MC; Grimm SA; Kumthekar PU; Bloch O
    J Clin Neurosci; 2019 Jun; 64():18-21. PubMed ID: 30948314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The detection of CMV pp65 and IE1 in glioblastoma multiforme.
    Lucas KG; Bao L; Bruggeman R; Dunham K; Specht C
    J Neurooncol; 2011 Jun; 103(2):231-8. PubMed ID: 20820869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.
    Wakefield A; Pignata A; Ghazi A; Ashoori A; Hegde M; Landi D; Gray T; Scheurer ME; Chintagumpala M; Adesina A; Gottschalk S; Hicks J; Powell SZ; Ahmed N
    J Neurooncol; 2015 Nov; 125(2):307-15. PubMed ID: 26341370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.
    Nair SK; De Leon G; Boczkowski D; Schmittling R; Xie W; Staats J; Liu R; Johnson LA; Weinhold K; Archer GE; Sampson JH; Mitchell DA
    Clin Cancer Res; 2014 May; 20(10):2684-94. PubMed ID: 24658154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
    Ghazi A; Ashoori A; Hanley PJ; Brawley VS; Shaffer DR; Kew Y; Powell SZ; Grossman R; Grada Z; Scheurer ME; Hegde M; Leen AM; Bollard CM; Rooney CM; Heslop HE; Gottschalk S; Ahmed N
    J Immunother; 2012; 35(2):159-68. PubMed ID: 22306904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
    Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
    J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of HIV infection on cytomegalovirus-specific immunity: T-cell responses to pp65 and IE1 before and after HAART may reflect altered cytomegalovirus biology.
    Scherrenburg J; Schellens IM; van Baarle D
    Antivir Ther; 2011; 16(4):565-75. PubMed ID: 21685544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
    Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
    J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
    Weathers SP; Penas-Prado M; Pei BL; Ling X; Kassab C; Banerjee P; Bdiwi M; Shaim H; Alsuliman A; Shanley M; de Groot JF; O'Brien BJ; Harrison R; Majd N; Kamiya-Matsuoka C; Fuller GN; Huse JT; Chi L; Rao G; Weinberg JS; Lang FF; Sawaya R; Shpall EJ; Rezvani K; Heimberger AB
    Clin Cancer Res; 2020 Jul; 26(14):3565-3577. PubMed ID: 32299815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytomegalovirus-mediated immunomodulation: Effects on glioblastoma progression.
    Foster H; Ulasov IV; Cobbs CS
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):273-276. PubMed ID: 28554666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants.
    Gibson L; Dooley S; Trzmielina S; Somasundaran M; Fisher D; Revello MG; Luzuriaga K
    J Infect Dis; 2007 Jun; 195(12):1789-98. PubMed ID: 17492595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.
    Dziurzynski K; Wei J; Qiao W; Hatiboglu MA; Kong LY; Wu A; Wang Y; Cahill D; Levine N; Prabhu S; Rao G; Sawaya R; Heimberger AB
    Clin Cancer Res; 2011 Jul; 17(14):4642-9. PubMed ID: 21490182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.
    Reap EA; Dryga SA; Morris J; Rivers B; Norberg PK; Olmsted RA; Chulay JD
    Clin Vaccine Immunol; 2007 Jun; 14(6):748-55. PubMed ID: 17442845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
    Ferguson SD; Srinivasan VM; Ghali MG; Heimberger AB
    Immunotherapy; 2016; 8(4):413-23. PubMed ID: 26973123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.
    Gibson L; Piccinini G; Lilleri D; Revello MG; Wang Z; Markel S; Diamond DJ; Luzuriaga K
    J Immunol; 2004 Feb; 172(4):2256-64. PubMed ID: 14764694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
    Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
    BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells.
    Bunde T; Kirchner A; Hoffmeister B; Habedank D; Hetzer R; Cherepnev G; Proesch S; Reinke P; Volk HD; Lehmkuhl H; Kern F
    J Exp Med; 2005 Apr; 201(7):1031-6. PubMed ID: 15795239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
    Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.